Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G‐CSF

The current salvage therapies for relapsed/refractory acute myeloid leukemia (AML) are unsatisfactory. Over the past 7 years, we have used two salvage regimens: fludarabine, cytarabine, and idarubicin with (FLAG‐IM) or without gemtuzumab ozogamicin (GO) (9 mg/m2 on Day 8) (FLAG‐I) in relapsed/refrac...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hematology 2009-11, Vol.84 (11), p.733-737
Main Authors: Martin, Mike G., Augustin, Kristan M., Uy, Geoffrey L., Welch, John S., Hladnik, Lindsay, Goyal, Sagun, Tiwari, Divya, Monahan, Ryan S., Reichley, Richard M., Cashen, Amanda F., Stockerl‐Goldstein, Keith, Westervelt, Peter, Abboud, Camille N., DiPersio, John F., Vij, Ravi
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aminoglycosides - administration & dosage
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Biological and medical sciences
Cytarabine - administration & dosage
Drug Evaluation
Female
Granulocyte Colony-Stimulating Factor - administration & dosage
Hematologic and hematopoietic diseases
Humans
Idarubicin - administration & dosage
Leukemia, Myeloid, Acute - drug therapy
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Middle Aged
Remission Induction
Retrospective Studies
Salvage Therapy - methods
Survival Analysis
Treatment Outcome
Vidarabine - administration & dosage
Vidarabine - analogs & derivatives
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The current salvage therapies for relapsed/refractory acute myeloid leukemia (AML) are unsatisfactory. Over the past 7 years, we have used two salvage regimens: fludarabine, cytarabine, and idarubicin with (FLAG‐IM) or without gemtuzumab ozogamicin (GO) (9 mg/m2 on Day 8) (FLAG‐I) in relapsed/refractory AML. Three‐quarters of patients also received concurrent G‐CSF. Seventy‐one patients were treated, 23 with FLAG‐I and 48 with FLAG‐IM. The median duration of follow‐up was 30.6 months. The treatment groups were well balanced with median ages of 48 years (range 18–70) and 47 years (range 20–68), unfavorable cytogenetics in 57% and 35%, prior allogeneic stem cell transplant in 43% and 42%, and CR1 duration
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.21545